| Literature DB >> 34252357 |
Yvonne D'Arcy1, Patrick Mantyh2, Tony Yaksh3, Sean Donevan4, Jerry Hall5, Mojgan Sadrarhami4, Lars Viktrup6.
Abstract
Osteoarthritis (OA) is a common difficult-to-treat condition where the goal, in the absence of disease-modifying treatments, is to alleviate symptoms such as pain and loss of function. Acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids are common pharmacologic treatments for OA. Antibodies directed against nerve growth factor (NGF-Abs) are a new class of agents under clinical investigation for the treatment of OA. This narrative review describes (and uses schematics to visualize) nociceptive signaling, chronification of pain, and the mechanisms of action (MOAs) of these different analgesics in the context of OA-related pain pathophysiology. Further, the varying levels of efficacy and safety of these agents observed in patients with OA is examined, based on an overview of published clinical data and/or treatment guidelines (when available), in the context of differences in their MOAs.Entities:
Keywords: Osteoarthritis; acetaminophen; mechanism of action; nerve growth factor; nonsteroidal anti-inflammatory drugs; opioids; pain
Mesh:
Substances:
Year: 2021 PMID: 34252357 DOI: 10.1080/00325481.2021.1949199
Source DB: PubMed Journal: Postgrad Med ISSN: 0032-5481 Impact factor: 3.840